These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 3877511)
1. Probable role of interleukin-1 in the pathogenesis of scleroderma. Alarcón-Segovia D; Alcocer-Varela J Arthritis Rheum; 1985 Nov; 28(11):1316-7. PubMed ID: 3877511 [No Abstract] [Full Text] [Related]
2. [Role of blood vessels in the pathogenesis of diffuse scleroderma]. Kamiński A Przegl Dermatol; 1974; 61(5):639-47. PubMed ID: 4278576 [No Abstract] [Full Text] [Related]
3. Connective tissue synthesis by cultured scleroderma fibroblasts. II. Incorporation of 3h-glucosamine and synthesis of glycosaminoglycans. Bashey RI; Perlish S; Nochumson S; Stephens RE; Fleischmajer R Arthritis Rheum; 1977 Apr; 20(3):879-85. PubMed ID: 856218 [TBL] [Abstract][Full Text] [Related]
4. Increased biosynthesis of glycosaminoglycans by scleroderma fibroblasts in culture. Bashey RI; Millan A; Jimenez SA Arthritis Rheum; 1984 Sep; 27(9):1040-5. PubMed ID: 6477654 [TBL] [Abstract][Full Text] [Related]
5. [Biosynthesis of glycosaminoglycans in skin of patients with progressive scleroderma]. Kreysel HW; Köhler A; Kleine TO Klin Wochenschr; 1973 Mar; 51(5):214-21. PubMed ID: 4120985 [No Abstract] [Full Text] [Related]
6. Altered collagen and glycosaminoglycan syntheses in familial scleroderma skin fibroblasts. Tajima S; Yamada H Dermatology; 1995; 191(2):115-8. PubMed ID: 8520056 [TBL] [Abstract][Full Text] [Related]
7. A radical proposal for the pathogenesis of scleroderma. Murrell DF J Am Acad Dermatol; 1993 Jan; 28(1):78-85. PubMed ID: 8425975 [TBL] [Abstract][Full Text] [Related]
8. [Some possible mechanisms in pathogenesis of systemic scleroderma]. Lebedev DA Ter Arkh; 1977; 49(11):126-30. PubMed ID: 605394 [No Abstract] [Full Text] [Related]
9. Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture. van den Hoogen FH; van der Kraan PM; Boerbooms AM; van den Berg WB; van Lier HJ; van de Putte LB Ann Rheum Dis; 1993 Oct; 52(10):758-61. PubMed ID: 8257212 [TBL] [Abstract][Full Text] [Related]
10. Immunological modulation of dermal fibroblasts in scleroderma. Perlish JS; Fleischmajer R Immunol Ser; 1989; 46():605-24. PubMed ID: 2488871 [TBL] [Abstract][Full Text] [Related]
11. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Brinckmann J; Kim S; Wu J; Reinhardt DP; Batmunkh C; Metzen E; Notbohm H; Bank RA; Krieg T; Hunzelmann N Matrix Biol; 2005 Oct; 24(7):459-68. PubMed ID: 16139999 [TBL] [Abstract][Full Text] [Related]
12. [Serum and urinary glycosaminoglycans in various forms of scleroderma]. Kniazev IuA; Khamaganova IV Revmatologiia (Mosk); 1986; (3):42-3. PubMed ID: 3538299 [No Abstract] [Full Text] [Related]
13. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. Feghali CA; Bost KL; Boulware DW; Levy LS J Rheumatol; 1992 Aug; 19(8):1207-11. PubMed ID: 1404155 [TBL] [Abstract][Full Text] [Related]
14. [Morphology, biochemistry and function of the proteoglycans in dermatology]. Kimmig J; Kreysel HW Klin Wochenschr; 1973 Mar; 51(5):207-13. PubMed ID: 4266464 [No Abstract] [Full Text] [Related]
15. An approach to experimental scleroderma, using urinary glycosaminoglycans from patients with systemic scleroderma. Ishikawa H; Suzuki S; Horiuchi R; Sato H Acta Derm Venereol; 1975; 55(2):97-107. PubMed ID: 48324 [TBL] [Abstract][Full Text] [Related]
19. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Leroy EC; Smith EA; Kahaleh MB; Trojanowska M; Silver RM Arthritis Rheum; 1989 Jul; 32(7):817-25. PubMed ID: 2665755 [No Abstract] [Full Text] [Related]
20. [Clinical evaluation of the determination of blood serum and urinary glycosaminoglycans in systemic scleroderma]. Fuzaĭlov OR; Astakhova TA; Guseva NG Ter Arkh; 1984; 56(5):45-9. PubMed ID: 6463886 [No Abstract] [Full Text] [Related] [Next] [New Search]